WEKO3
アイテム
{"_buckets": {"deposit": "d4a70bfa-a564-40f7-afe6-8cd5b7ea9325"}, "_deposit": {"created_by": 1, "id": "83860", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "83860"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00083860", "sets": ["29"]}, "author_link": ["1011725", "1011720", "1011724", "1011719", "1011718", "1011726", "1011721", "1011722", "1011723", "1011727"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2021-11-04", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives\nIntegrin α5β1 is considered one of the most prominent targets among RGD binding integrin receptors for tumor diagnosis. Our goal is to develop a peptide-based radiotracer for PET imaging of α5β1-integrin in different types of cancers.\n\nMethods\nA peptide, with a sequence of KSSPHSRN(SG)5RGDSP (PR_b), was conjugated with a PEG molecule to obtain [64Cu]PEG-PR_b. PET imaging was performed in tumor-bearing mice. Ex vivo biodistribution and immunohistochemistry were employed to study the metabolism and specificity of the tracer.\n\nResults\nPET imaging revealed a higher tumor uptake of [64Cu]PEG-PR_b than that of [64Cu]PR_b (3.5%ID/g versus 1.8%ID/g) at 1 hour postinjection. Ex vivo biodistribution indicated that PEGylation delayed the kidney clearance of the tracers.\n\nConclusion\nWe anticipated clinical applicability of [64Cu]PEG-PR_b for imaging of α5β\n1 by PET.\n", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第61回日本核医学会学術総会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kuan, Hu"}], "nameIdentifiers": [{"nameIdentifier": "1011718", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "謝, 琳"}], "nameIdentifiers": [{"nameIdentifier": "1011719", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張, 一鼎"}], "nameIdentifiers": [{"nameIdentifier": "1011720", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "破入, 正行"}], "nameIdentifiers": [{"nameIdentifier": "1011721", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張, 明栄"}], "nameIdentifiers": [{"nameIdentifier": "1011722", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011723", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lin, Xie", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011724", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011725", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Hanyu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011726", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1011727", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/83860", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-11-01"}, "publish_date": "2021-11-01", "publish_status": "0", "recid": "83860", "relation": {}, "relation_version_is_last": true, "title": ["In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide"], "weko_shared_id": -1}
In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide
https://repo.qst.go.jp/records/83860
https://repo.qst.go.jp/records/83860ed1472aa-4ac6-413b-8525-4215611cfff7
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-11-01 | |||||
タイトル | ||||||
タイトル | In vivo PET imaging of cancer α5β1-integrin using a pegylated peptide | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kuan, Hu
× Kuan, Hu× 謝, 琳× 張, 一鼎× 破入, 正行× 張, 明栄× Kuan, Hu× Lin, Xie× Zhang, Yiding× Masayuki, Hanyu× Zhang, Ming-Rong |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives Integrin α5β1 is considered one of the most prominent targets among RGD binding integrin receptors for tumor diagnosis. Our goal is to develop a peptide-based radiotracer for PET imaging of α5β1-integrin in different types of cancers. Methods A peptide, with a sequence of KSSPHSRN(SG)5RGDSP (PR_b), was conjugated with a PEG molecule to obtain [64Cu]PEG-PR_b. PET imaging was performed in tumor-bearing mice. Ex vivo biodistribution and immunohistochemistry were employed to study the metabolism and specificity of the tracer. Results PET imaging revealed a higher tumor uptake of [64Cu]PEG-PR_b than that of [64Cu]PR_b (3.5%ID/g versus 1.8%ID/g) at 1 hour postinjection. Ex vivo biodistribution indicated that PEGylation delayed the kidney clearance of the tracers. Conclusion We anticipated clinical applicability of [64Cu]PEG-PR_b for imaging of α5β 1 by PET. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第61回日本核医学会学術総会 | |||||
発表年月日 | ||||||
日付 | 2021-11-04 | |||||
日付タイプ | Issued |